Status:
COMPLETED
Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Brief Summary
Background: \- A special brain circuit is important for helping us keeping an eye open for things that are going on around us, even when we are not directly paying attention to them. This circuit see...
Detailed Description
Objective: To test a neural circuit explanation for a visuospatial attention abnormality seen in schizophrenia. Specifically, the aim is to test whether broad monitoring deficits may be based on a dis...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- All participants:
- Age 18 through 55.
- Normal or corrected to normal visual acuity (at least 20/80)
- Participants with menat illness:
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Ability to give written informed consent
- Four week of stable pharmacological treatment (same psychiatric medication at same dose or no medication)
- EXCLUSION CRITERIA:
- All participants:
- Presence of ferromagnetic metal objects in the body, implanted electronic devices or any other counter -indication for MRI.
- Claustrophobia
- Left handed or ambidextrous
- History of myocardial infarction or heart failur, which may cause asymptomatic brain lesions
- Uncontrolled high blood pressure (resting systolic greater than 150 or diastolic greater than 90 mm Hg)
- Neurological conditions likely to impair cognitive function such as stroke, seizures, dementia or organic brian syndrome
- Any condition likely to impair cognitive function such as mental retardation or severe pharmacological sedation
- Current use of vasodilating beta-blockers (carvedilol, labetalol or nebivolol)
- Alcohol or substance abuse or dependence other than nicotine within the last 6 months
- Pregnancy, verified by urin pregnancy test for females during screening and on the day of the scan.
- Healthy Controls:
- Current psychiatric Axis I disorder or Axis II schizophrenia spectrum disorder, verified by Structured Clinical Interview for DSM-IV (SCID)
Exclusion
Key Trial Info
Start Date :
July 3 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 24 2014
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01399437
Start Date
July 3 2011
End Date
December 24 2014
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue
Catonsville, Maryland, United States, 21228